Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer. Salerno addressed the topic of NCCN guideline updates in breast cancer at the 2016 NCCN Annual Conference.

There is compelling evidence that hypofractionation to the whole breast elicits equivalent, if not better, outcomes for women compared with the conventional regimen. Data from two large studies showed that in addition to outcomes, cosmetic outcomes were also the same, if not better, and toxicity was more tolerable for patients.

Salerno says the tweaking of the guidelines to state that hypofractionation is “preferred” is an important change. She says she hopes that it will lead to greater adoption throughout the United States.

View more from the 2016 NCCN Annual Conference

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

NCCN Annual Conference

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer